Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
出版年份 2015 全文链接
标题
Next Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
作者
关键词
Weight management, Medications, Cardiometabolic risks
出版物
Current Cardiology Reports
Volume 17, Issue 5, Pages -
出版商
Springer Nature
发表日期
2015-04-17
DOI
10.1007/s11886-015-0590-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Benefit-Risk Assessment of Orlistat in the Treatment of Obesity
- (2014) Priya Sumithran et al. DRUG SAFETY
- Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies
- (2014) V Margaret Jackson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The New Weight-Loss Drugs, Lorcaserin and Phentermine-Topiramate
- (2014) Steven Woloshin et al. JAMA Internal Medicine
- Pharmacotherapy for obesity: novel agents and paradigms
- (2014) Sean Manning et al. Therapeutic Advances in Chronic Disease
- Reducing the Risk of Developing Diabetes
- (2013) Thomas Ransom et al. Canadian Journal of Diabetes
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. CIRCULATION
- Recent advancements in drug treatment of obesity
- (2013) R. Carter et al. CLINICAL MEDICINE
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Cardiovascular disease in childhood: the role of obesity
- (2013) Despina Herouvi et al. EUROPEAN JOURNAL OF PEDIATRICS
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Long-term Drug Treatment for Obesity
- (2013) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- New and Emerging Drug Molecules Against Obesity
- (2013) Melvin George et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- New pharmacological approaches for obesity management
- (2013) Christian F. Rueda-Clausen et al. Nature Reviews Endocrinology
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs
- (2013) E. W. Chan et al. Obesity Reviews
- Do we need anti-obesity drugs?
- (2012) Vojtěch Hainer et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
- (2011) Steven P Marso et al. Diabetes & Vascular Disease Research
- Novel strategy for the use of leptin for obesity therapy
- (2011) Charmaine S Tam et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?
- (2010) G.A. Kennett et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
- (2008) M. Nauck et al. DIABETES CARE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started